StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Research analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.

Bio-Path Price Performance

Shares of BPTH opened at $1.16 on Friday. Bio-Path has a one year low of $0.59 and a one year high of $12.00. The stock’s fifty day moving average is $0.90 and its 200-day moving average is $1.21.

Institutional Investors Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.